Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies.
AIDS
; 25(11): 1365-9, 2011 Jul 17.
Article
em En
| MEDLINE
| ID: mdl-21522004
ABSTRACT
OBJECTIVE:
We evaluated the long-term efficacy of raltegravir according to HIV-1 subtype (B and non-B) using data from three phase III studies in treatment-experienced (BENCHMRK-1 and 2) and treatment-naive (STARTMRK) HIV-infected patients.METHODS:
HIV-1 subtypes were identified from baseline plasma specimens using genotypic data of the PhenoSense GT test (Monogram Biosciences, South San Francisco, California, USA). Non-B subtypes were combined for the current analyses due to small numbers of each specific subtype. An observed failure approach was used (only discontinuations due to lack of efficacy were treated as failures). Resistance evaluation was performed in patients with documented virologic failure.RESULTS:
Seven hundred and forty-three patients received raltegravir and 519 received comparator (efavirenz in STARTMRK; optimized background therapy in BENCHMRK). Non-B subtype virus (A, A/C, A/D, A/G, A1, AE, AG, B/G, BF, C, D, D/F, F, F1, G, and complex) was isolated at baseline in 98 (13%) raltegravir recipients and 62 (12%) comparator recipients. Subtypes AE and C were most common, isolated in 41 and 43 patients, respectively. The proportion of raltegravir recipients achieving HIV RNA less than 50 copies/ml was similar between non-B and B subtypes (STARTMRK 94.5 vs. 88.7%; BENCHMRK-1 and 2 66.7 vs. 60.7%); change in CD4 cell count also was similar between non-B and B subtypes (STARTMRK 243 vs. 221 cells/µl; BENCHMRK-1 and 2 121 vs. 144 cells/µl). Phenotypic resistance to raltegravir in non-B virus was associated with integrase mutations observed previously in subtype B virus.CONCLUSION:
In phase III studies in treatment-naive and treatment-experienced patients, raltegravir showed comparable and potent clinical efficacy against B and non-B HIV-1 subtypes.
Texto completo:
1
Eixos temáticos:
Pesquisa_clinica
Base de dados:
MEDLINE
Assunto principal:
Pirrolidinonas
/
Infecções por HIV
/
HIV-1
/
Antirretrovirais
/
Produtos do Gene env do Vírus da Imunodeficiência Humana
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article